Prevention of Onset and Transition to an Advanced Form of Diabetic Retinopathy in Children

Sponsor
University Hospital Ostrava (Other)
Overall Status
Recruiting
CT.gov ID
NCT05615740
Collaborator
(none)
150
1
2
43
3.5

Study Details

Study Description

Brief Summary

The primary goal of the project is to create a normative database from data collected from a healthy pediatric population. A secondary aim is to compare normative data with data from pediatric patients with pre-existing type 1 diabetes mellitus.

Condition or Disease Intervention/Treatment Phase
  • Diagnostic Test: Optical coherence tomography (OCTA)
N/A

Detailed Description

Diabetic retinopathy, or damage to the retina caused by diabetes, is one of the most common complications in all patients with newly diagnosed diabetes mellitus of both types. These are mainly pathological changes affecting the vascular supply of the retina, which precede changes affecting the peripheral nervous system.

Children and in general patients with type I diabetes mellitus are around 0.6% of the population in the long term. the first changes in the retinal vessels can usually be expected after 2-5 years from the first detection of the disease. These changes are diagnosed using a biomicroscopic examination of the fundus.

Until recently, the only possible examination method was fluorescein angiography (FAG). It is an invasive examination with a fluorescein solution administered into a peripheral vein through a cannula and further photo documentation of the flow dynamics through the vascular bed in blue (cobalt) light. The flow time in individual phases of filling is recorded.

The disadvantage is the necessary cooperation of the child, the need to establish peripheral venous access, the risk of an allergic reaction to the contrast material, and the duration of the examination lasting two or more hours.

These disadvantages disappeared with the advent of optical coherence tomography and the angiographic mode - OCTA.

OCTA can detect the passage of individual blood elements (mostly erythrocytes) through capillaries and larger vessels in real-time and thus compile maps of individual vascular networks in the retina and choroid. The advantage is that the examination is not invasive, it is not necessary to inject a dye into the patient's bloodstream and no special preparation is required. The device is classified as a Class 1 laser, which is safe for the human eye. The examination is not painful or uncomfortable.

Due to the relatively short period of use in practice, there is still a lack of data from findings in a healthy population. In the past, normative databases of adult patients were compiled for comparing the state of the healthy central area of the eye using OCTA. Data for the child population, especially the Central European one, is missing or has been collected on a small sample only.

The primary goal of the project is to create a normative database from data collected from a healthy pediatric population. A secondary aim is to compare normative data with data from pediatric patients with pre-existing type 1 diabetes mellitus.

It is anticipated that 100-150 children aged 6-15 will be enrolled at the Centre for Visually Impaired Children of the University of Ostrava as part of regular check-ups. Depending on the degree of cooperation of the child, the examination takes around two minutes.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
150 participants
Allocation:
Non-Randomized
Intervention Model:
Parallel Assignment
Intervention Model Description:
The study subjects will be enrolled into two groups - healthy pediatric population and children with diabetes mellitus.The study subjects will be enrolled into two groups - healthy pediatric population and children with diabetes mellitus.
Masking:
None (Open Label)
Primary Purpose:
Diagnostic
Official Title:
Prevention of Onset and Transition to an Advanced Form of Diabetic Retinopathy in Children
Actual Study Start Date :
May 2, 2022
Anticipated Primary Completion Date :
Nov 1, 2025
Anticipated Study Completion Date :
Dec 1, 2025

Arms and Interventions

Arm Intervention/Treatment
Active Comparator: Healthy pediatric patients

Healthy pediatric patients will undergo optical coherence tomography.

Diagnostic Test: Optical coherence tomography (OCTA)
OCTA can detect the passage of individual blood elements (mostly erythrocytes) through capillaries and larger vessels in real-time

Active Comparator: Children with diabetes mellitus

Children with diabetes mellitus will undergo optical coherence tomography.

Diagnostic Test: Optical coherence tomography (OCTA)
OCTA can detect the passage of individual blood elements (mostly erythrocytes) through capillaries and larger vessels in real-time

Outcome Measures

Primary Outcome Measures

  1. Vascular density in central and peripheral retina - healthy subjects [3 years]

    The primary goal of the project is measurement of vascular density in central and peripheral retina in healthy subjects using OCT Spectralis (Heidelberg Engineering, Germany). Vascular density is ratio between areas with and without vascular tissue. Data will be analysed by ImageJ software (National Institutes of Health, USA). Normative data will be collected from healthy individuals 6-15 years old.

Secondary Outcome Measures

  1. Vascular density in central and peripheral retina - diabetic patients [3 years]

    The secondary goal of the project is measurement of vascular density in central and peripheral retina in diabetic patients using OCT Spectralis (Heidelberg Engineering, Germany). Data will be analysed by ImageJ software (National Institutes of Health, USA). Normative data will be collected from diabetic patients 6-15 years old shortly after being diagnosed and compared with results obtained in the healthy group.

Eligibility Criteria

Criteria

Ages Eligible for Study:
6 Years to 15 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  • emmetropia

  • slight refractive error

  • best-corrected visual acuity equal to or better than 6/6 Schnellen optotypes

Exclusion Criteria:
  • general disease that by its nature affects or can affect the retina and the vascular system of the eye

  • concomitant vascular or other retinal diseases

Contacts and Locations

Locations

Site City State Country Postal Code
1 University Hospital Ostrava Ostrava Moravian-Silesian Region Czechia 70852

Sponsors and Collaborators

  • University Hospital Ostrava

Investigators

  • Principal Investigator: Michal Koubek, MD, University Hospital Ostrava

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
University Hospital Ostrava
ClinicalTrials.gov Identifier:
NCT05615740
Other Study ID Numbers:
  • 03_RVO-FNOs_2022
First Posted:
Nov 14, 2022
Last Update Posted:
Nov 14, 2022
Last Verified:
Nov 1, 2022
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by University Hospital Ostrava
Additional relevant MeSH terms:

Study Results

No Results Posted as of Nov 14, 2022